Ipsen (FR:IPN) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ipsen’s Iqirvo (elafibranor) shows promising long-term efficacy and safety in treating primary biliary cholangitis (PBC), with significant improvements in symptoms such as fatigue and pruritus over three years. The data, presented at the AASLD congress, bolsters Iqirvo’s potential as a leading treatment choice for PBC, having been approved in several major markets in 2024.
For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.